Should we Use Cell of Origin and Dual-Protein Expression in Treating DLBCL?
Treatment outcomes in diffuse large B-cell lymphoma (DLBCL) following standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy is highly variable and dependent on a number of clinical, biologic, and genetic features. The identification of molecular heterogeneity via gene expression profiling dichotomizes patients based on the cell of origin (COO) model into germinal center B-cell like (GCB) and activated B-cell like (ABC) subsets, with ABC-DLBCL having a worse outcome.
A safety profile of medications used to treat Waldenström's macroglobulinemia. Expert Opin Drug Saf. 2018 May 17;: Authors: García-Sanz R, Jiménez C, González de la Calle V, Sarasquete ME Abstract INTRODUCTION: Waldenström's macroglobulinemia (WM) is a B-cell lymphoproliferative disease with serum IgM monoclonal component and bone marrow infiltration by lymphoplasmacytic lymphoma. Traditional therapy was based on that regimens used for closely related entities, such as chronic lymphocytic leukemia or multiple myeloma. This resulted in a lack of drugs specifically approved...
Conditions: Multiple Myeloma; CLL; Chronic Lymphocytic Leukemia; Lymphoma Interventions: Radiation: Total Body Irradiation; Procedure: Haploidentical Stem Cell Transplantation; Biological: CD56-Enriched Donor Lymphocyte Infusion; Drug: Bendamustine; Drug: Fludarabine; Drug: Rituximab Sponsors: Noah Merin; Miltenyi Biotec GmbH; TEVA Not yet recruiting
Based on the study of 205 Chinese patients with multiple myeloma, we demonstrated a prevalence of 9.3% of BRAF V600E mutation, the highest hitherto reported. Additionally, BRAF V600E mutation was found to be associated with hypercalcemia and a male predominance. In subgroup analysis, the BRAF V600E mutation showed prognostic impact on overall survival in younger patients less than 65 years of age. This is the first large scale study revealing the prevalence and clinicopathological significances of BRAF V600E mutation in Chinese myeloma.
Recent advances in treatment have extended the survival of patients with multiple myeloma. This improvement in itself poses challenges given the length of time that patients live with myeloma, its physical complications, and toxicities of treatment. Thus, improvements in maintaining quality of life are essential, and part of this challenge involves learning how to use new therapeutic agents optimally. Panobinostat is the first histone deacetylase inhibitor approved for the treatment of multiple myeloma.
Outcomes in acute myeloid leukemia (AML) have been correlated with predictive and prognostic factors including age, performance status, comorbidities, cytogenetics and molecular mutations. Retrospective review of 137 adult AML patients identified 3+7 induction and absence of monosomal karyotype to positively predict complete remission while positive predictors of overall survival were younger age and the absence of monosomal karyotype.
Authors: Li Q, Pang Y, Liu T, Tang Y, Xie J, Zhang B, Chen H Abstract Mesenchymal stem cells (MSCs) have been used in hematopoietic stem cell transplantation for years. However, the safety of MSCs applied in various types of hematologic malignancy has not been comprehensively explored. In the present study, the effects of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) on six representative hematologic malignancy cell lines were explored, including leukemia, multiple myeloma and lymphoma cells. Direct and indirect co-culture models were established, and cell proliferation was assessed by carboxyfluor...
Several prognostic factors such as intermediate karyotype, presence of 5-9% bone marrow blasts and platelet count
Acute myeloid leukemia (AML) is the second most common leukemia among adults. Although the median age at diagnosis is 67 years, with approximately one-third of patients aged 75 years or older, limited treatment options exist for the elderly, who have 5-year survival rates of only 5%. A systematic review was conducted to examine effectiveness and safety outcomes of treatment regimens in elderly ( ≥60 years old) patients with AML.Published literature on the topic was scant, and the review included only 22 articles examining outcomes.
Antibody-drug conjugates (ADCs) are tripartite molecules consisting of a monoclonal antibody, a covalent linker, and a cytotoxic payload. ADC development has aimed to target the specificity inherent in antigen-antibody interactions in order to deliver potent cytotoxins preferentially to tumor cells and maximize antitumor activity while simultaneously minimizing off-target toxicity. The earliest ADCs provided disappointing results in the clinic, but the lessons learned regarding the need for human or humanized antibodies, more stable linkers, and higher potency payloads led to improved ADCs.
To the Editor,